MONDAY, May 24, 2021 (HealthDay News) – High levels of eicosapentaenoic acid (EPA), an omega-3 fatty acid (ω-3), are of no benefit to patients at high risk for cardiovascular events May 16 in JAMA, according to a study published online Cardiology at the American College of Cardiology Annual Meeting, held May 15-17, Virtual.
Steven E. Nissen, MD, of the Cleveland Clinic, and colleagues randomly assigned 13,078 high cardiovascular risk patients with elevated triglyceride levels and low levels of high density lipoprotein cholesterol to receive 4 g -3-carboxylic acid or an inert comparator daily, Corn oil. The plasma levels of EPA or docosahexaenoic acid (DHA) were determined at the start of the study and after 12 months.
The researchers found that the median plasma levels at 12 months in patients with ω-3-carboxylic acid were 89 μg / ml for EPA and 91 μg / ml for DHA, with upper tertile levels of 151 and 118 μg / ml, respectively. The adjusted hazard ratios for cardiovascular events with the highest tertile of plasma levels reached were 0.98 (95 percent confidence interval, 0.83 to 1.16; P = 0.81) for EPA and 1.02 (95 percent confidence interval, Confidence interval, 0.86 to 1.20; P = 0.85) for DHA compared to corn oil. The results were similar in sensitivity analyzes based on changes in plasma and erythrocyte levels of EPA and DHA and for subgroups of primary and secondary prevention.
“Our analysis shows no evidence that high levels of EPA have cardiovascular benefits,” Nissen said in a statement. “Previous studies have shown that in people with very high triglycerides, fish oil supplements or icosapentethyl help lower them. However, based on the current evidence, there is no reduction in the overall cardiovascular risk for patients. ”Several authors disclosed financial ties to pharmaceutical companies, including AstraZeneca, which sponsored the study.
Summary / full text
Copyright © 2021 Health Day. All rights reserved.